Bailey S, Roberts A, Brock C, Price L, Craft A W, Kilkarni R, Lee R E J, Skillen A W, Skinner R
Department of Child Health, University of Newcastle upon Tyne, Newcastle upon Tyne NE1 4LP, UK.
Br J Cancer. 2002 Nov 4;87(10):1092-8. doi: 10.1038/sj.bjc.6600608.
One aspect of concern for survivors of Wilms' tumour has been the late outcome in terms of renal function. Previous studies have documented low glomerular filtration rate and high blood pressure in some patients. Furthermore, disorders in tubular function (especially urinary concentration defects) have been suggested but not confirmed in small studies. The aim of this study was to determine the prevalence and nature of subclinical and overt glomerular, proximal and distal renal tubular toxicity in a population based cohort of survivors of Wilms' tumour. Forty patients (24 female) with a median age of 4.3 years (3 months-11.8 years) at diagnosis were studied. Median follow-up was 8.8 (range 0.06-27.5) years. Glomerular filtration rate was measured by (51)Cr-EDTA plasma clearance, proximal tubular function by electrolyte fractional excretions, urine excretion of low molecular weight proteins (retinol-binding protein) and renal tubular enzymes (alanine aminopeptidase; N-acetylglucosaminidase) and distal tubular function by the osmolality of the first two urines of the day on 3 consecutive days. Renal size (ultrasound) and blood pressure were also measured. Mean (range) glomerular filtration rate was 100 (61-150) ml min(-1) 1.73 m(-2). Nine were below the reference range for healthy individuals with two kidneys. Most serum electrolyte concentrations (sodium, potassium, chloride, calcium, magnesium and phosphate) fell within the normal range for age, as did the fractional excretions. The values that fell outside the normal range were only marginally abnormal. Subclinical measures of tubular toxicity (retinal-binding protein, alanine aminopeptidase, N-acetylglucosaminidase) were abnormal in only four patients. Thirty-seven patients achieved maximal urine osmolalities > or =800 mOsm kg(-1), but three failed to achieve this value even after DDAVP administration. Two patients had evidence of increased urinary albumin excretion. Compensatory renal hypertrophy was seen in all but two patients, but blood pressure was within normal limits in all patients. Current and past treatment for Wilms' tumour does not have any clinically important nephrotoxic effect in the majority of patients. This finding will enable paediatric oncologists to reassure patients and parents that treatment for Wilms' tumour rarely causes long-term renal impairment.
肾母细胞瘤幸存者令人担忧的一个方面是其肾功能的远期预后。既往研究记录了部分患者肾小球滤过率低和高血压的情况。此外,有研究提示存在肾小管功能障碍(尤其是尿浓缩功能缺陷),但在一些小型研究中未得到证实。本研究的目的是确定在一个基于人群的肾母细胞瘤幸存者队列中,亚临床及显性肾小球、近端和远端肾小管毒性的患病率及性质。研究对象为40例诊断时中位年龄4.3岁(3个月至11.8岁)的患者(24例女性)。中位随访时间为8.8年(范围0.06 - 27.5年)。通过(51)铬-乙二胺四乙酸血浆清除率测定肾小球滤过率,通过电解质排泄分数、低分子量蛋白质(视黄醇结合蛋白)尿排泄及肾小管酶(丙氨酸氨基肽酶;N - 乙酰氨基葡萄糖苷酶)测定近端肾小管功能,通过连续3天每天晨尿的前两次尿液的渗透压测定远端肾小管功能。同时测量肾脏大小(超声检查)和血压。平均(范围)肾小球滤过率为100(61 - 150)ml·min⁻¹·1.73 m⁻²。9例低于有两个肾脏的健康个体的参考范围。大多数血清电解质浓度(钠、钾、氯、钙、镁和磷酸盐)及排泄分数均在年龄正常范围内,超出正常范围的值仅轻度异常。仅4例患者的肾小管毒性亚临床指标(视黄醇结合蛋白、丙氨酸氨基肽酶、N - 乙酰氨基葡萄糖苷酶)异常。37例患者最大尿渗透压≥800 mOsm/kg⁻¹,但3例即使给予去氨加压素后仍未达到该值。2例患者有尿白蛋白排泄增加的证据。除2例患者外,其余患者均见代偿性肾肥大,但所有患者血压均在正常范围内。肾母细胞瘤的当前及既往治疗在大多数患者中未产生任何具有临床意义的肾毒性作用。这一发现将使儿科肿瘤学家能够向患者及家长保证,肾母细胞瘤治疗很少导致长期肾功能损害。